构建和表征环氧金属有机框架和大豆的多糖聚合物复合物载体:增强黄素的输送
Shumin Wang1, Shengnan Wang2, Lanxin Zhang1
1College of Food Science and Technology, Bohai University, Jinzhou, 121013, China.
Food chemistry
|December 12, 2024
概括
新的复合材料载体结合了环氧金属有机框架 (CD-MOF) 和大豆多糖 (SHP) 增强了功能因素的传递. 这些载体通过在胃中保护黄素并将其释放到肠道中来改善黄素的利用.
科学领域:
- 材料科学 材料科学 材料科学
- 聚合物科学 聚合物科学
- 纳米技术 纳米技术
背景情况:
- 开发功能因素的先进载体对于有针对性的输送和提高有效性至关重要.
- 环氧金属有机框架 (CD-MOF) 为封装提供独特的结构性质.
- 大豆聚糖 (SHP) 是复合材料的生物相容聚合物矩阵.
研究的目的:
- 为了合成和描述新的复合材料载体,将CD-MOF与SHP集成在一起.
- 使用这些载体,评估黄素 (Cur) 的封装效率和释放特征.
- 评估复合载体在增强功能因子传递方面的潜力,特别是对黄素.
主要方法:
- 一个立方结构复合载体的合成 (γ-CD-MOF@SHP).
- 使用富里埃变换红外光谱仪 (FTIR),拉曼光谱,粉末X射线衍射 (XRD) 和差分扫描热度计 (DSC) 进行了表征.
- 在模拟生理条件下评估黄素加载效率和体外释放概况.
主要成果:
- 成功合成了CD和SHP之间具有键相互作用的γ-CD-MOF@SHP复合载体.
- 在复合结构中确认了黄素的封装.
- 在35°C时优化了加载效率,在24小时浸泡后,黄素与载体的比率为1:3.
- SHP证明对黄素有保护作用,调节其释放以增强肠道吸收.
结论:
- 开发的 γ-CD-MOF@SHP 复合载体显示出控制和增强功能因素传递的巨大潜力.
- MOFs和SHP聚合物的组合为稳定和调节活性化合物的释放提供了一个有希望的策略.
- 这种方法可以带来更好的治疗结果和各种功能成分的利用.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


